Enhanced adhesion/migration and induction of Pyk2 expression in K562 cells following imatinib exposure

Adelina Ovcharenko, Galit Granot, Oshrat Hershkovitz Rokah, Jennifer Park, Ofer Shpilberg, Pia Raanani

Research output: Contribution to journalArticlepeer-review

6 Scopus citations

Abstract

Concern about extramedullary relapse (EMR) despite favorable response in the bone marrow has been raised with the use of imatinib for treatment of chronic myeloid leukemia (CML).In the present study we show an increase in adhesion, migration and invasion capabilities of the CML cell line K562 following imatinib administration. Imatinib induced upregulation of Pyk2 mRNA and protein levels. Pyk2 inhibition resulted in a reduction of K562 cells' adhesion and migration subsequent to imatinib treatment. This effect was similar to that shown by us previously with all trans retinoic acid (ATRA) in the acute promyelocytic leukemia (APL) cell line NB4.Our data pinpoint Pyk2 as a shared key mediator of targeted-therapy induced adhesion and migration and may implicate that targeting Pyk2 may serve as an effective therapeutic strategy to reduce EMR in APL and CML.

Original languageEnglish
Pages (from-to)1729-1736
Number of pages8
JournalLeukemia Research
Volume37
Issue number12
DOIs
StatePublished - 1 Dec 2013
Externally publishedYes

Keywords

  • Adhesion
  • Chronic myeloid leukemia
  • Extramedullary disease
  • Imatinib
  • Migration
  • Pyk2

Fingerprint

Dive into the research topics of 'Enhanced adhesion/migration and induction of Pyk2 expression in K562 cells following imatinib exposure'. Together they form a unique fingerprint.

Cite this